IBD
Conditions
Keywords
durg efficacy, Crohn's Disease, Ustekinumab, Intestinal Epithelial Fucosylation
Brief summary
The loss of response rate of ustekinumab(UST) is high, and the specific mechanism has not yet been elucidated. Molecular markers that can accurately predict the efficacy of UST are urgently needed to provide theoretical basis for guiding individualized treatment. Therefore, this study intends to explore the impact of intestinal epithelial fucosylation levels on the efficacy of UST in patients with Crohn's disease(CD), aiming to provide predictable molecular markers for UST to accurately treat CD.
Interventions
None listed
Sponsors
Second Affiliated Hospital of Wenzhou Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Diagnosed with moderate to severe Crohn's disease 2. Receiving treatment with ustekinumab 3. Received colonoscopy and collected intestinal tissue samples before and after treatment
Exclusion criteria
1. Pregnancy 2. Hypersensitivity to any component of ustekinumab 3. Cognitive or developmental disabilities prevent you from completing this study 4. Combined with diseases such as RA, diabetes, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis and tumors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical remission rate at 24 week | at 24 week | A specialist will evaluate the HBI score at 24 week based on the patient's clinical symptoms and determine whether the patient is in clinical remission based on the score. |
Countries
China
Outcome results
None listed